Discover our tumor models for oncology proof of concept
Oncodesign Services offers a range of discovery & preclinical services built upon a tumor models of syngeneic, cell-derived xenograft (CDX) and patient-derived xenograft (PDX) tumors.
Over 500 syngeneic, CDX and PDX tumor models are established in-house, covering 20 organ origins and up to 35 pathologies: bladder, blood, brain, breast, cervix, colon, head and neck, kidney, liver, lung, skin (melanoma), muscle, osteosarcoma, ovary, pancreas, prostate, Schwann cell, stomach and more. These cover solid tumors, hematological malignancies and metastasis models.
Tumors are used for in vivo modeling, in vitro screening and for target expression analysis. The tumors are stored as viable frozen stocks for propagation and often in FFPE blocks for ex vivo analysis of the TME. Please ask for slide samples.
Popular Human CDX Models
Breast MX-1 | MDA-MB-468 | MCF-7 Colon HCT-116| Ls174T Lung Calu-6 | NCI-H46 Prostate PC-3 Brain U-87 MG
Well Characterized Mouse Syngeneic Models
Bladder MBT-2 Breast EMT6 | 4T1 (Mets to lung) Colon C26 | C38 | MC38 | CT26 (Mets to lung) Kidney renca (mets to lung) Melanoma B16F10 (Mets to lung) Mesothelioma AB12 Liver Hepa 1-6 Lung LLc1 (Mets to lung) Pancreas Pan02 Lymphoma A20 Plasmacytoma MPC-11 Osteosarcoma NCTC-2472 (Mets)
Patient-Derived Xenografts (PDX)
Oncodesign has collected PDX tumors for over 25 years, in partnership with the IMODI consortium. Currently, we have >200 unique tumors, covering 19 indications. These tumors have been characterized in regard to:
- Conservation of phenotype and genotype
- Gene expression stability
- Gene mutation status
- Response to standard of care (SOC)
If the model you need requires a specific gene expression or gene mutation, please ask us to query the transcriptome. Many tumors are available as tissue microarray slides, cut from FFPE blocks.
Colon DHD/K12/TRb (PROb)* Brain GV1A1* Bladder AY-27 Breast MAT-B-III Head & Neck FAT-7 Brain GS-9L Prostate R3327H* Prostate Mat-Ly-Lu* Breast DMBA-induced
CASE STUDY with tumor model :
The U-87-MG brain glioblastoma CDX was used as a SC model in rats for a study of sorafenib and temozolomide. Negative control animals had exponential tumor growth after about 30 days. Sorafenib delayed the tumor growth and temozolomide completely attenuated the tumor growth in this model.